Navigation Links
PROLOR Biotech To Present New Preclinical Data On Its Long-Acting Clotting Factor VIIa At Leading European Scientific Conference
Date:2/6/2013

WARSAW, Poland and NES-ZIONA, Israel, Feb. 6, 2013 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH), today announced that the company will present new data on its long-acting clotting factor VIIa (Factor Vlla-CTP) at the Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD).  PROLOR's Factor VIIa-CTP is a next-generation investigational therapy currently in advanced preclinical development for the potential treatment of patients with hemophilia.

Currently, factor VIIa therapy is available only as an intravenous (IV) formulation, which can be onerous for patients.  The company will present new data at the EAHAD Congress showing that PROLOR's long-acting Factor VIIa-CTP has demonstrated the potential for subcutaneous (SC) administration in addition to standard IV dosing.  PROLOR researchers believe that a long-acting factor VIIa therapy that could be administered subcutaneously, using a simple injection, would allow children and adults with hemophilia to easily self-administer factor Vlla at home on a prophylactic basis, significantly improving their quality of life. 

Dr. Abraham Havron , CEO of PROLOR, commented, "We have previously presented data in animal models of hemophilia showing that Factor Vlla-CTP demonstrated superiority across key efficacy and safety parameters as compared to current factor VIIa therapy.  The potential for SC administration may represent a major competitive advantage for our long-acting Factor Vlla-CTP, and we expect to initiate a Phase II clinical trial in hemophilia patients in late 2013 or early 2014."

The data will be presented from 5:00-8:00pm local time on February 6, 2013 by Dr. Gili Hart , Director of Pre-Clinical Affairs at PROLOR and head of the company's long-acting clotting factors program.  The European Association fo
'/>"/>

SOURCE PROLOR Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
2. PROLOR Biotech Announces Presentation of Data on Its Long-Acting Clotting Factors at World Federation of Hemophilia World Congress
3. PROLOR Biotech To Present Data On Its Long-Acting Human Growth Hormone At International NeuroEndocrine Meeting
4. PROLOR Biotech to Present Data on Its Long-Acting Human Growth Hormone at Pediatric Endocrinology Meeting
5. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
6. Puma Biotechnology Announces Completion of Private Placement
7. Animal Biotechnology - Technologies, Markets and Companies
8. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
9. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
10. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
11. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 2015 Spirax Sarco, the leader ... their newly designed, state-of-the-art website in the first ... effectively promotes the Spirax Sarco brand, company capabilities, ... that a site visitor might be looking for ... industries serviced, the latest company news, careers, and ...
(Date:4/16/2015)... CA (PRWEB) April 16, 2015 Cytokinetics, ... to report first quarter results on Thursday, April 30, ... Cytokinetics’ senior management will host a conference call at ... results and the company’s outlook for the future. , ... be accessed from the homepage and in the Investor ...
(Date:4/16/2015)... , April 16, 2015  Schulman Associates IRB, Inc., ... has signed a long-term lease on Laboratory Drive in ... Carolina . The location will house review board ... provide high quality reviews and customer service to clients. ... represented Schulman in the deal, while Capital Associates ...
(Date:4/16/2015)... CHARLOTTE, N.C. (PRWEB) April 16, 2015 ... North Carolina at Charlotte (UNC Charlotte) spin-out company, ... David L. Cooper, Ph.D., M.D., as Chief Operating ... 20 years of experience in developing clinical diagnostic ... oncology and infectious disease. , Cooper’s extensive career ...
Breaking Biology Technology:Spirax Sarco website has a new look 2Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3Schulman IRB to Open Office in Research Triangle Park, N.C. 2OncoTAb Names Dr. David L. Cooper as COO 2
... Inc. (Nasdaq: VVUS ), a biopharmaceutical company ... today reported its highlights and financial results for the third ... Quarter Highlights , In the third quarter of ... pivotal 56-week studies, EQUIP (OB-302) and CONQUER (OB-303), evaluating the ...
... Nov. 3 Sangamo BioSciences, Inc. (Nasdaq: SGMO ) ... provide an update on the progress of Sangamo,s ZFP Therapeutic(TM) ... at 2:20 pm ET on Tuesday, November 10, 2009 at ... be held in New York City. , The presentation will ...
... WILMINGTON, Delaware, November 3 The ... Technologies Market, (2009 - 2014),published by MarketsandMarkets ( ... stem cell market. It identifies and analyzes,the main ... services, technologies, and applications submarkets in different,geographic regions. ...
Cached Biology Technology:VIVUS Reports Third Quarter 2009 Highlights and Financial Results 2VIVUS Reports Third Quarter 2009 Highlights and Financial Results 3VIVUS Reports Third Quarter 2009 Highlights and Financial Results 4VIVUS Reports Third Quarter 2009 Highlights and Financial Results 5VIVUS Reports Third Quarter 2009 Highlights and Financial Results 6VIVUS Reports Third Quarter 2009 Highlights and Financial Results 7VIVUS Reports Third Quarter 2009 Highlights and Financial Results 8Sangamo BioSciences Announces Presentation at Merriman Curhan Ford's Investor Summit 2009 2MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014 2MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014 3
(Date:4/2/2015)... -- Fingerprint Cards (FPC) has received an ... distributor World Peace Industrial Group (WPI), part of WPG ... major part of the shipments will take place during ... manufacturers in China . The order ... revenue guidance of + 1 000 MSEK for 2015.  ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, ... million users across iOS and Android ... begun integrating biofeedback into the platform to allow patients ... outcomes. For the first time, patients will be able ... a dose impacts important biometrics, such as glucose levels ...
(Date:3/31/2015)... 31, 2015   Guidepoint , a leading global ... Post-Surgical Pain Management TRACKER, part of the Guidepoint ... in the medical device and therapeutics markets. The Post-Surgical ... treatment volumes, market share, and adoption rates across three ... joint surgery. The Post-Surgical Pain Management TRACKER ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... the dead bone of a transplanted skeletal graft into living ... gene therapy to stimulate the body into treating the foreign ... thousands of cancer and trauma patients each year who suffer ... online Feb. 13 and will appear in the March 1 ...
... Malignancies Program at the H. Lee Moffitt Cancer Center ... of the experimental drug Revlimid showing promise as an ... a form of pre-leukemia. Given in pill form, Revlimid ... nourish tumors (anti-angiogenesis) and stimulates the immune system to ...
... many years, DNA and proteins have been,viewed as ... with RNA seen,as little more than a messenger ... Whitehead Institute for Biomedical Research,and Massachusetts Institute of ... regulate thousands of human genes--more,than one third of ...
Cached Biology News:Gene therapy converts dead bone graft to new, living tissue 2Gene therapy converts dead bone graft to new, living tissue 3Gene therapy converts dead bone graft to new, living tissue 4Leukemia Drug Breakthrough Study In New England Journal Of Medicine 2NYU researchers simulate molecular biological clock 2
... 1-D PAGE Cleavable ICAT ... Targeted Protein ID and ... Gel Electrophoresis (PAGE), isotope-coded ... cleavable-linker technology to facilitate ...
Supplemental reagent for annexin V assay....
Antibody Purification Specificity: Antibody Purification ...
Large-fragment, single-stranded carrier DNA of the highest quality, perfectly suited for all types of yeast transformation....
Biology Products: